DiscoveryProbe™ FDA-approved Drug Library: High-Throughput, Clinically Relevant Screening Resource

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 clinically approved bioactive compounds with diverse mechanisms of action, facilitating high-throughput screening (HTS) and drug repositioning (APExBIO). This library includes drugs approved by multiple international agencies (FDA, EMA, HMA, CFDA, PMDA), ensuring global regulatory coverage. Recent studies demonstrate its utility in identifying novel agonists and antagonists for G-protein-coupled receptors (GPCRs), including TAS2R14, a highly promiscuous bitter taste receptor (Fierro et al., 2023). Compounds are provided as 10 mM DMSO solutions, supporting robust experimental reproducibility and integration into automated workflows. The library is manufactured and quality-controlled by APExBIO, a recognized supplier of research reagents.

Biological Rationale

Drug discovery increasingly relies on high-content and high-throughput screening of bioactive compounds to accelerate target validation and repositioning. The DiscoveryProbe™ FDA-approved Drug Library is composed of compounds already validated for safety and efficacy in humans, reducing translational uncertainty (APExBIO). GPCRs represent the largest family of membrane proteins in humans, with approximately 800 members, and are targeted by over 450 FDA-approved drugs—about one-third of all FDA-approved pharmaceuticals (Fierro et al., 2023). Screening libraries enriched in such compounds enable rapid exploration of approved chemical space for novel biological activities, off-target mechanisms, and pathway modulation. The inclusion of drugs approved by multiple regulatory agencies (FDA, EMA, HMA, CFDA, PMDA) broadens the library’s relevance across global disease models. This resource is especially valuable in cancer research, neurodegenerative disease drug discovery, and studies of signal pathway regulation.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library encompasses compounds with well-defined mechanisms, including receptor agonists and antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators. Representative molecules such as doxorubicin (a DNA intercalator and topoisomerase inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor) illustrate the functional diversity. The library supports discovery of both known and novel interactions—such as identification of new GPCR ligands—by leveraging pre-validated pharmacology (Fierro et al., 2023). Compounds are supplied at 10 mM in DMSO, maintaining chemical integrity and enabling dose–response analyses across multiple assay platforms. The inclusion of both agonists and antagonists facilitates balanced investigation of activation and inhibition mechanisms within cellular and biochemical assays.

Evidence & Benchmarks

• Experimental screening of an FDA-approved drug library (~1,800 compounds) identified 200 new agonists and 10 new antagonists for the TAS2R14 GPCR (Fierro et al., 2023, https://doi.org/10.1007/s00018-023-04765-0).
• 9% of tested pharmaceutical drugs activated TAS2R14, with nine compounds active at sub-micromolar concentrations (Fierro et al., 2023, DOI).
• Approximately 52% of GPCR-targeting FDA-approved drugs are antagonists, illustrating the library’s suitability for antagonist discovery (Fierro et al., 2023, DOI).
• The library format (pre-dissolved 10 mM DMSO solutions) ensures stability for 12 months at -20°C and 24 months at -80°C, supporting long-term studies (APExBIO).
• High-throughput screening with the DiscoveryProbe™ set has been cited as an enabling step for mechanistic target identification in translational workflows (Internal Article).

This article extends prior reviews by providing detailed evidence for GPCR ligand discovery and clarifies the translational benchmarks outlined in "DiscoveryProbe™ FDA-Approved Drug Library: A Paradigm for...", which focused on phenotypic screening breadth, while this article details mechanistic and regulatory aspects. For a discussion of workflow integration and translational acceleration, see "Translational Acceleration: Mechanistic Drug Discovery an..."—this article updates key benchmarks with recent empirical data.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library finds application in:

• High-throughput screening (HTS) for novel target discovery.
• High-content phenotypic assays (HCS) for pathway and disease model interrogation.
• Drug repositioning, enabling rapid identification of new indications for approved molecules.
• Pharmacological target validation in cancer, neurology, and immunology research.
• Signal pathway regulation studies, including identification of off-target effects.

Its global regulatory coverage facilitates translational studies with direct clinical relevance.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for every assay type: Some may interfere with fluorescence or luminescence due to intrinsic properties.
• Library does not contain investigational or preclinical compounds: Only clinically approved or pharmacopeia-listed molecules are included.
• Concentration may require adjustment: While 10 mM DMSO is standard, some targets may require alternate dosing for optimal activity windows.
• Off-target effects are possible: Compounds may act via multiple mechanisms, necessitating orthogonal validation.
• Library is not a substitute for comprehensive ADMET profiling: Further pharmacokinetic and toxicology studies are required for novel indications.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is delivered in multiple formats—96-well microplates, deep-well plates, and 2D barcoded screw-top tubes—to facilitate integration into automated liquid handling and screening platforms. The 10 mM DMSO format is compatible with most assay types, including cell-based, biochemical, and biophysical screens. Compounds are QC-verified for identity and solubility. Storage at -20°C allows for 12 months of stability; -80°C extends this to 24 months. Shipping is performed on blue ice for evaluation samples; larger sets can be shipped at room temperature or on blue ice as requested. Researchers should employ positive and negative controls, as well as replicate testing, to ensure robust results. For advanced workflow design and strategic integration, this thought-leadership article details approaches for linking mechanistic screens to translational objectives, complementing the practical focus here.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO provides a rigorously curated, globally relevant set of bioactive compounds for high-throughput and high-content screening. Its clinical validation, diverse mechanisms of action, and robust format make it a critical resource for accelerating drug repositioning, pharmacological target identification, and mechanistic research in cancer, neurodegenerative disease, and beyond. Future updates may integrate additional compounds as new drugs are approved, further expanding the library’s translational impact.

For detailed specifications or ordering information, visit the DiscoveryProbe™ FDA-approved Drug Library product page.